These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 12759197)

  • 1. Principles of drug abuse liability assessment in laboratory animals.
    Ator NA; Griffiths RR
    Drug Alcohol Depend; 2003 Jun; 70(3 Suppl):S55-72. PubMed ID: 12759197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abuse liability assessment in preclinical drug development: predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models.
    Teuns GB; Geys HM; Geuens SM; Stinissen P; Meert TF
    J Pharmacol Toxicol Methods; 2014; 70(3):295-309. PubMed ID: 24632211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current approaches and issues in non-clinical evaluation of abuse and dependence.
    Moser P; Wolinsky T; Castagné V; Duxon M
    J Pharmacol Toxicol Methods; 2011; 63(2):160-7. PubMed ID: 20868759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Principles of initial experimental drug abuse liability assessment in humans.
    Griffiths RR; Bigelow GE; Ator NA
    Drug Alcohol Depend; 2003 Jun; 70(3 Suppl):S41-54. PubMed ID: 12759196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug abuse potential evaluation in animals.
    Balster RL
    Br J Addict; 1991 Dec; 86(12):1549-58. PubMed ID: 1786486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug self-administration methods in abuse liability evaluation.
    Henningfield JE; Cohen C; Heishman SJ
    Br J Addict; 1991 Dec; 86(12):1571-7. PubMed ID: 1786489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proactive nonclinical drug abuse and dependence liability assessment strategy: a sponsor perspective.
    Swedberg MD
    Behav Pharmacol; 2013 Sep; 24(5-6):396-402. PubMed ID: 23907375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Principles of laboratory assessment of drug abuse liability and implications for clinical development.
    Carter LP; Griffiths RR
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S14-25. PubMed ID: 19443137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abuse liability assessment of anxiolytics/hypnotics: rationale and laboratory lore.
    Evans SM; Critchfield TS; Griffiths RR
    Br J Addict; 1991 Dec; 86(12):1625-32. PubMed ID: 1686197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preference procedures for testing the abuse liability of drugs in humans.
    De Wit H
    Br J Addict; 1991 Dec; 86(12):1579-86. PubMed ID: 1786490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How good are current approaches to nonclinical evaluation of abuse and dependence?
    Moser P; Wolinsky T; Duxon M; Porsolt RD
    J Pharmacol Exp Ther; 2011 Mar; 336(3):588-95. PubMed ID: 21098089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse liability studies of opioid agonist-antagonists in humans.
    Preston KL; Jasinski DR
    Drug Alcohol Depend; 1991 Jun; 28(1):49-82. PubMed ID: 1884671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The gold-standard in preclinical abuse liability testing: It's all relative.
    Gauvin DV; Zimmermann ZJ; Baird TJ
    J Pharmacol Toxicol Methods; 2018; 94(Pt 2):36-53. PubMed ID: 30125620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of abuse liability of stimulant drugs in humans: a methodological survey.
    Foltin RW; Fischman MW
    Drug Alcohol Depend; 1991 Jun; 28(1):3-48. PubMed ID: 1679387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing the abuse liability of anxiolytic and hypnotic drugs in humans.
    de Wit H; Griffiths RR
    Drug Alcohol Depend; 1991 Jun; 28(1):83-111. PubMed ID: 1679388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing abuse liability during drug development: changing standards and expectations.
    Schoedel KA; Sellers EM
    Clin Pharmacol Ther; 2008 Apr; 83(4):622-6. PubMed ID: 18212799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological evaluation of compounds for their physical dependence potential and abuse liability. XIII. Drug Testing Program of the Committee on Problems of Drug Dependence, Inc.
    Jacobson AE
    NIDA Res Monogr; 1989; 95():556-77. PubMed ID: 2641053
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetic considerations in abuse liability evaluation.
    Farré M; Camí J
    Br J Addict; 1991 Dec; 86(12):1601-6. PubMed ID: 1786493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse.
    Swedberg MD
    J Pharmacol Toxicol Methods; 2016; 81():295-305. PubMed ID: 27235786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.
    Born S; Gauvin DV; Mukherjee S; Briscoe R
    Regul Toxicol Pharmacol; 2017 Jun; 86():181-192. PubMed ID: 28279667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.